Background. Hypocalcemia occurs after total thyroidectomy (TT) for Graves disease via parathyroid injury and/or from increased bone turnover. Current management is to supplement calcium after surgery. This study evaluates the impact of preoperative calcium supplementation on hypocalcemia after Graves TT. Methods. A prospective study of patients with Graves disease undergoing TT was performed. Patients with Graves disease managed over a 9-month period took 1 g of calcium carbonate (CC) three times a day for 2 weeks before TT. Those managed the previous year without supplementation served as historic controls. Age-, gender-, and thyroid weight-matched, non-Graves TT patients were procedure controls. Patient demographics, postoperative laboratory values, complaints, and medications were reviewed. Parathyroid hormone (PTH)-based postoperative protocols dictated postoperative CC and calcitriol use. Results. Forty-five patients with Graves disease were treated with CC before TT, and 38 patients with Graves disease were not. Forty control subjects without Graves disease were identified. Age, gender, and thyroid weight were comparable. Preoperative calcium and PTH levels were equivalent. PTH values immediately after surgery, at postoperative day 1, and at 2-week follow-up were equivalent. Postoperative use of scheduled CC (p = 0.10) and calcitriol (p = 0.60) was similar. Postoperatively, patients with untreated Graves disease had lower serum calcium levels than pretreated patients with Graves disease or control subjects without Graves disease (8.3 mg/dL vs. 8.6 vs. 8.6, p = 0.05). Complaints of numbness and tingling were more common in nontreated Graves disease (26 %) than in pretreated Graves disease (9 %) or in control subjects without Graves disease (10 %, p \ 0.05). Conclusions. Calcium supplementation before TT for Graves disease significantly reduced biochemical and symptomatic postoperative hypocalcemia. Preoperative calcium supplementation is a simple treatment that can reduce symptoms of hypocalcemia after Graves TT.
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A well-known complication of bilateral thyroid surgery is compromise of the parathyroid glands resulting in transient symptomatic hypocalcemia or potentially even permanent hypoparathyroidism. [1] [2] [3] [4] This complication has plagued thyroid surgeons and has led to many modifications to the operative procedure, including subtotal thyroidectomy to minimize disruption to the parathyroid glands, as well as abandonment of central ligation of the inferior thyroid artery. 5 As the blood supply to the parathyroid glands had become better understood, total thyroidectomy (TT) is now routinely performed with division of the vascular supply as it directly enters the capsule of the gland. In addition to surgical technique modifications, there are a variety of clinical practices to try to prevent symptomatic hypocalcemia,, including selective calcium and vitamin D supplementation based on postoperative parathyroid hormone (PTH) levels, and routine supplementation for all patients without evaluation of PTH levels in the postoperative period. 3, [6] [7] [8] [9] Patients with Graves disease have much higher rates of symptomatic hypocalcemia after TT than patients undergoing TT for other diagnoses. 1, 3, [10] [11] [12] [13] [14] Factors contributing to this increased rate of hypocalcemia after surgery include increased bone hunger resulting from thyrotoxic osteodystrophy, increased release of calcitonin during gland manipulation during surgery, and increased inflammation and friability of the gland, making the procedure technically more demanding and therefore placing the parathyroid glands at increased risk for injury. 1, 12, 15 Because TT is the operation of choice for the surgical management of Graves disease, it is critical that the risk of symptomatic hypocalcemia is minimized. 10, 14, 16, 17 Some authors have proposed the use of calcium in the preoperative period for patients with Graves disease; however, to our knowledge, no study has reported on how this practice influences patient outcome. 12 We hypothesized that pretreating patients with Graves disease with calcium supplementation before TT would decrease the frequency of symptomatic postoperative hypocalcemia.
METHODS
After institutional review board approval was obtained, a retrospective review was performed on a prospectively maintained database of all patients undergoing thyroid surgery at a large university-based endocrine surgery practice. As of January 2013, all patients with a diagnosis of Graves disease undergoing TT were advised to take 1 g of calcium carbonate (CC) without vitamin D (Tums, GlaxoSmithKline, Middlesex, UK) three times a day in the 2 weeks leading up to surgery. This dose and scheduling were selected because they were comparable to the postoperative dosing and schedule used for patients in a protocol-driven fashion. Patients with Graves disease who took preoperative CC supplementation were identified as the study cohort. Patients with Graves disease undergoing TT in the preceding calendar year (2012) and who had not received any preoperative CC supplementation were identified and used as disease-specific controls. Additional patients undergoing TT alone for other indications during the same time period (2012-2013) were selected to serve as contemporary procedure control subjects. Patients undergoing central neck dissection were excluded. The procedure controls were matched in a one-to-one fashion by age, gender, and thyroid weight in an effort to control for surgical difficulty due to enlarged gland size.
Standard practice within the study institution includes the measurement of preoperative calcium and PTH levels for patients undergoing thyroid surgery. 18 Preoperative patient demographics and laboratory values were included. Saturated solution of potassium iodine (SSKI) 0.2 mL three times a day for 7-10 days before surgery is prescribed to the patients. Patients who are pregnant or who have an allergy to iodine are not prescribed SSKI. Use of SSKI in patients unable to take antithyroid medications and/or in patients who are still hyperthyroid is dependent on surgeon discretion and differs between providers. 19 A PTH level was routinely sent on all patients in the immediate postoperative period, whereas only those patients observed overnight had serum calcium levels checked 4 hours after surgery, along with both a serum calcium and PTH level the morning of postoperative day 1 at the surgeon's discretion. Although patients with Graves disease were routinely placed on scheduled CC after surgery, patients without Graves disease had supplementation of scheduled CC based on a protocol driven by and determined on the basis of postoperative PTH level (Table 1) . 7, 8 Use of calcitriol was based on a postoperative PTH level protocol, regardless of the diagnosis. Immediate postoperative PTH levels were further characterized as [10, 2-10, and \2 pg/mL.
Pathology reports were reviewed for details regarding thyroid gland weight. Patient-reported complaints during their hospital stay and at time of postoperative follow-up were noted, as were any telephone calls, emergency room visits, or readmissions for complaints specific to signs and symptoms of hypocalcemia (numbness, tingling, muscle cramping, tetany).
Statistical analysis was performed by SPSS Statistics, version 21 (IBM). Continuous variables were compared by ANOVA, and categorical variables were compared by chisquare test. Variables following a nonparametric distribution were compared with the Kruskal-Wallis test. Serum calcium levels were plotted over time and analyzed using a 
RESULTS
A total of 123 patients were identified for inclusion in the study. Between January and September 2013, 45 patients with Graves disease underwent TT and were pretreated with CC for 2 weeks before surgery. In 2012, 38 patients with Graves disease underwent TT and were not given CC before surgery. Spanning both time periods, 40 patients undergoing TT only for a diagnosis other than Graves disease were identified as procedure controls. These patients were not given CC before surgery either. The patients serving as procedural controls had the diagnoses of well-differentiated thyroid cancer (n = 15, 38 %), multinodular goiter (n = 18, 45 %), and benign adenoma (n = 7, 18 %).
The mean patient age was 42 ± 16 years and was comparable between groups (p = 0.51, Table 2 ). The majority of patients were female (86 %). Serum calcium (9.2 ± 0.6 mg/dL) and PTH (51.9 ± 66 mg/dL) levels at time of initial preoperative consultation, before any supplementation, were equivalent across the groups (p = 0.97 and p = 0.83, respectively). Although no change in practice regarding SSKI use occurred during the study period, we noted a difference in use between the Graves disease cohorts. Only 62 % of the pretreated patients with Graves disease were given SSKI, while 84 % of the nonpretreated patients with Graves disease were given SSKI (p = 0.03). Parathyroid autotransplantation was required most often in the pretreated patients with Graves disease (22 %) compared to the untreated patients with Graves disease (8 %) and patients without Graves disease (3 %, p = 0.01). The mean thyroid specimen weight on final pathology was 37.5 ± 36 g and was also similar between groups (p = 0.72).
Upon reviewing medication records and discharge orders, a similar number of patients across groups were sent home with scheduled CC supplementation ( Table 3 , p = 0.10). Overall use of calcitriol was infrequent (24 %) and was comparable between groups (p = 0.60). The overall rate of reported numbness or tingling symptoms attributed to symptomatic hypocalcemia was 15 % for the entire study population. Preoperative supplementation with CC resulted in a rate of symptomatic hypocalcemia of only 10 %, equivalent to patients without Graves disease. However, patients with Graves disease who did not undergo preoperative supplementation with CC reported symptoms of numbness and tingling 2.6 times more often (26 %) (p = 0.049). The patients with Graves disease who did not undergo pretreatment with CC before TT were noted to have significantly lower serum calcium levels 4 hours after surgery compared to the patients with Graves disease pretreated with CC or patients undergoing TT for other diagnoses (8.3 vs. 8.6 mg/dL, respectively, p = 0.05) ( Table 4) . PTH levels immediately after surgery were equivalent between groups (p = 0.42). When PTH level was stratified as undetectable, low, or normal, there was also no difference between groups (p = 0.84). By postoperative day 1, and at the time of follow-up visits, serum calcium levels and PTH levels were equivalent. When we plotted out the serum calcium levels over time, levels were not found to differ significantly, although this may have been the result of the overall low number of patients in each group with values drawn at all four time points (p = 0.18, Fig. 1 ).
DISCUSSION
This study represents what is to our knowledge the first report of preoperative CC supplementation for patients with Graves disease undergoing TT, and it demonstrates its efficacy in minimizing symptomatic hypocalcemia in the postoperative period. Although other authors have proposed this practice, none has reported on associated patient outcomes. 12 Given the multifactorial causes of hypocalcemia after TT for Graves disease, preoperative CC supplementation allows for replenishment of whole-body calcium stores, which may be depleted as a result of increased bone metabolism resulting from thyrotoxic osteodystrophy. With this contributing factor addressed in the preoperative period by CC supplementation, patients with Graves disease undergoing TT are found to experience rates of symptomatic hypocalcemia equivalent to patients undergoing TT for other disease processes. The observed equivalence of PTH levels between the study cohorts further supports the non-parathyroid-mediated causes for increased hypocalcemia rates historically described in patients with Graves disease undergoing TT. 1, 12, 13 As previously mentioned, patients with Graves disease have multiple proposed mechanisms that contribute to decreased serum calcium after TT separate from parathyroid function. Thyroid hormone has a direct effect on osteoclasts, which stimulates bone turnover. This in turn can lead to increased serum alkaline phosphatase, serum osteocalcin, urinary calcium, and urinary deoxypyridinoline. 12, 15 This continued bone destruction and subsequent loss of calcium via the urine results in depletion of wholebody stores of calcium. Previous authors have also demonstrated concomitant vitamin D deficiency to place patients at increased risk for symptomatic hypocalcemia or tetany after TT for Graves disease, but this was not necessarily a deficiency caused by the Graves disease. 20 Given the influence vitamin D has on the absorption of calcium, an underlying deficiency would understandably result in exacerbation of hypocalcemia, as well as make calcium replacement more difficult without also addressing the vitamin D deficiency. Last, it has also been postulated that during manipulation of the gland at time of surgery, calcitonin is released in an abnormal fashion. 16 Although measurements of alkaline phosphatase, osteocalcin, calcitonin, and urinary measures of calcium and deoxypyridinoline were not measured and were outside the scope of this study, the similar postoperative PTH levels we found favor these alternative explanations.
Given the proximity of the parathyroid glands to the thyroid capsule, as well as the shared blood supply via the inferior thyroid artery, parathyroid damage still contributes to symptomatic hypocalcemia after TT for any diagnosis. The literature reports that rates of transient hypocalcemia after TT range from 6 to 72 % for all diagnoses. [1] [2] [3] [4] 13, 21, 22 The wide range in the reported rates of transient hypocalcemia is in part due to the variability of definition from study to study. Additional factors noted to place patients at increased risk for transient and/or permanent hypoparathyroidism after thyroid surgery include the extent of thyroid resection, recurrent goiter, Graves disease, hospital volume, and female gender. 21 In an additional study, Thomusch et al. also found central ligation of the inferior thyroid artery to result in much higher rates of hypoparathyroidism as a result of compromise of the parathyroid blood supply. 5 However, this technique has long since been abandoned. Specific to patients with Graves disease, SSKI or Lugol solution is often administered in the preoperative period in efforts to decrease vascularity and friability of the gland. 19, 23 More recently, the value of its use has been called into question. 24 It is unclear how the use or omission of SSKI would affect dissection and preservation of the parathyroid glands. Although we observed a lower rate of SSKI use in the patients with Graves disease taking CC before surgery, it is unclear if this directly resulted in the increased rate of parathyroid autotransplantation. Regardless, this did not result in alteration of the postoperative PTH levels and therefore did not negatively affect serum calcium levels. With a 15 % overall rate of symptomatic hypocalcemia in the present study, these values fall well within the previously published rates of symptomatic hypocalcemia after TT for all diagnoses, not just Graves disease.
In the American Thyroid Association (ATA) guidelines for the management of hyperthyroidism, TT, radioactive iodine ablation, and antithyroid medications are listed as the ''three effective and relative safe initial treatment options'' for patients diagnosed with Graves disease. 10 Despite this recommendation, a recent survey of the membership of three major international endocrinology organizations demonstrated that surgery as the first-line therapy is used only 0.7 % of the time worldwide, and for only 0.9 % of cases in the United States. 9 However, there were selective instances when TT was the preferred firstline treatment: patients with severe ophthalmopathy (18.5 %), and women wanting to conceive in the near future (20.3 %). For patients who do not experience remission after 12-18 months of antithyroid medications, TT has also proven to be more cost-effective in the definitive management of Graves than either lifelong antithyroid medication or radioactive iodine ablation. 25 The data presented here add to the growing literature demonstrating that TT for Graves disease does not pose any greater risk of hypoparathyroidism than TT for benign causes. 13, 14, [26] [27] [28] With a failure rate of radioactive iodine ablation between 10 and 38 %, the documented costeffectiveness of TT as definitive management, and the severe, life-threatening adverse effects from antithyroid medications, it is surprising that surgical management of Graves disease has not become more widely adopted. 10, 14, [29] [30] [31] [32] Another caveat to the ATA guidelines is that near-total or TT should be performed by a high-volume surgeon to ensure optimal outcomes and to minimize risk of permanent complications. 10 This recommendation is based on several studies showing superior patient outcomes for both benign and malignant thyroid conditions when thyroid surgery is performed by a high-volume thyroid surgeon. [33] [34] [35] Our institution is a high-volume practice, and thus the rates of transient hypocalcemia are low and reflect this expertise. As a result of our growing institutional experience, nearly half of all patients within our institution are referred for surgical management at time of initial Graves diagnosis for definitive therapy. Other authors have also observed excellent outcomes after TT for Graves disease, as well as lower rates of disease recurrence or persistence compared to nonsurgical therapies. 27, 28 Although this study reflects a prospective alteration in clinical practice, it uses an historic cohort for comparison, which may result in some limitations to our conclusions. It also reflects the practice at a single high-volume institution, where the surgical management of Graves disease makes up a significant proportion of the thyroid surgical volume. Despite the relative high volume of surgery for Graves disease, the cohort groups are still relatively small, which may lead to underpowering of our analysis. Additionally, our results regarding equivalent PTH levels may not be applicable to lower-volume centers. Because not all patients had serum calcium and/or PTH levels assessed both on the day of surgery and on postoperative day 1, our assessment of patient trends over time are based on a limited number of patients. This is in part due to differences in surgeon practices regarding overnight observation versus same-day surgery, as well as differences in laboratory evaluation preferences. We suspect these observed changes in serum calcium levels would reach significance with a larger patient population; however, additional studies are needed. Also, patients did not have thyroid function measured on the day of surgery to determine whether the degree and/or duration of the hyperthyroid or euthyroid state influenced the severity of bone hunger experienced by the patient and therefore influenced the degree of serum calcium alteration in the postoperative period. Because serum albumin and vitamin D are not routinely assessed as part of the preoperative laboratory evaluation for thyroid surgery at the study institution, it is possible that additional variables influence calcium metabolism that were not captured.
CONCLUSION
Preoperative supplementation of patients with Graves disease with CC before TT minimizes the drop in serum calcium after surgery and reduces the number of episodes of symptomatic hypocalcemia during the postoperative period. Because immediate postoperative PTH levels were equivalent across groups, the mechanism resulting in a greater incidence of symptomatic hypocalcemia after TT for Graves disease is not due to increased injury to the parathyroid glands at a high-volume endocrine surgery practice. Counseling patients to take 1 g of CC three times a day is a simple intervention to add to the preoperative preparation for the Graves patient.
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